The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited ...

HOUSTON — Bruton's tyrosine kinase inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib have revolutionized the ...

Careful management by a team of specialists is needed to balance disease control and fetal health in patients with CML who are pregnant or trying to become prengant.

Nuvalent shows promise with strong clinical data for zidesamtinib and NVL-655 in treating ROS1- and ALK-positive NSCLC. Read ...

In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the ...

A small clinical trial suggests that a duo of drugs can extend survival for people battling advanced kidney cancer.

DelveInsight's BTK Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, ...

Physicians in the US, Germany, and France show gaps in their knowledge of the treatment of of refractory/relapsed chronic ...

Shenzhen Genuine Biotech Co. Ltd. has disclosed tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) allosteric inhibitors reported to be useful for the treatment of cancer.

Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients with Renal Cell Carcinoma Following an Immune Checkpoint ...

ORR increased from 60.9% with osimertinib alone to 90.5% with the addition of the MET-selective tyrosine kinase inhibitor (TKI) savolitinib. The disease control rate increased from 87.0% with ...